Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers

T Nakatani, S Kuriyama, K Tominaga, T Tsujimoto, A Mitoro, M Yamazaki, H Tsujinoue, H Yoshiji, S Nagao, H Fukui

Abstract

Background—When recombinant adenoviruses are infused directly into the circulation, transgene expression is almost completely restricted to the liver.

Aims—Efficiency and safety of adenovirus mediated gene transfer into damaged livers were examined in mice with liver cirrhosis or fulminant hepatitis.

Methods—Liver cirrhosis and fulminant hepatitis were induced by intraperitoneal administration of thioacetamide and d-galactosamine followed by lipopolysaccharide, respectively. Mice were infused with adenoviruses carrying the Escherichia coli β-galactosidase gene, lacZ gene, into the tail vein. Transduction efficiency of the lacZ gene was estimated histochemically by X-gal staining and quantitatively using a chemiluminescent assay. Activation of adenovirus specific T cells and development of neutralising antibodies against adenovirus were also examined.

Results—Histochemical evaluation revealed that approximately 40%, 80%, and 40% of cells in normal, cirrhotic, and fulminant hepatitis livers, respectively, were stained blue using X-gal staining. Quantitative analyses revealed that levels of lacZ expression in cirrhotic livers were approximately 2.5-fold and sixfold greater than those in normal and fulminant hepatitis livers, respectively. Although transgene expression in fulminant hepatitis livers was significantly lower than that in normal livers, marked levels of transgene expression were achieved even in fulminant hepatitis livers. Significant adverse effects of adenoviruses were not observed in damaged livers. There were no significant differences in cellular or humoral immune responses to adenoviruses among animals with normal, cirrhotic, and fulminant hepatitis livers.

Conclusions—Our results suggest that gene therapy with adenoviruses may be used efficiently and safely, even in patients with severe liver disease.

(Gut 2000;47:563–570)

Keywords: adenovirus; transduction efficiency; safety; liver cirrhosis; fulminant hepatitis

Recently, intensive efforts have been made towards developing practical strategies for gene therapy against a variety of diseases. In vivo gene therapy is more practical than ex vivo therapy because the latter requires invasive surgical procedures to collect target cells for genetic modification. Adenoviruses are ideally suited for in vivo gene therapy because of their high titres and ability to mediate a high level of transgene expression in a wide variety of cells and tissues. Adenovirus serotypes 2 and 5, which cause respiratory diseases in humans, have been developed for use in gene therapy; both belong to subgroup C adenoviruses which are not associated with human malignancies.1

The natural tropism of adenoviruses for airway epithelia has been exploited in the development of gene therapy for cystic fibrosis.2–4 Another application of recombinant adenoviruses, which is different from the usual spectrum of naturally acquired infections, is in liver directed gene therapy. Recombinant adenoviruses infused directly into the circulation primarily target hepatocytes.5–9 Hence in vivo gene transfer into the liver using adeno viral vectors are promising gene therapy strategies.

Despite these advances, several factors significantly limit the use of current early gene region 1 (E1) deleted adenoviral vectors. Cellular and humoral immune responses directed against the virus and transgene encoded proteins, which results in transient gene expression, and inability to readminister vectors of the same serotype have been described.10 Furthermore, hepatotropic transgene expression induced by adeno viral vectors results in hepatic injury.11 Therefore, it is important to estimate the efficiency and safety of adenovirus mediated gene transfer into damaged livers because it is possible that patients with liver diseases may undergo gene therapy in the future. However, these issues remain to be examined.

In the present study, we investigated liver cirrhosis and fulminant hepatitis as these are the most serious of the various liver diseases. We estimated efficiency of adenovirus medi-
ated transfer of a reporter gene into mice with cirrhosis of the liver or fulminant hepatitis. We also examined the cytopathic effects of adenoviruses to estimate the safety of adenoviral administration into animals with severely damaged livers.

**Methods**

**ADENOVIRAL VECTOR**

Adex1CA LacZ adenovirus was generously provided by Dr Izumu Saito (Institute of Medical Science, University of Tokyo, Tokyo, Japan) and details of the construction procedures have been described previously. This adenovirus vector carries an adenovirus serotype 5 genome lacking the E1A and E1B regions to prevent viral replication, and contains the *Escherichia coli* β-galactosidase gene, lacZ, as a reporter gene between the CAG promoter composed of the cytomegalovirus enhancer plus the chicken β-actin promoter and the rabbit β-globin polyadenylation signal in place of the E1A and E1B regions. This adenovirus vector also lacks the E3 region to make space for exogenous DNA. Although deletion of the E3 region has no role in preventing adenoviral DNA replication, its absence could affect the severity of viral cytopathic effects and immune responses. The recombinant adenovirus was propagated and isolated in 293 cells, as described previously. The viral solution was stored at −150°C until use. To titre the viral solution, an aliquot of virus was serially diluted and assayed for ability to form plaques on 293 cell monolayers, as described previously. A single batch of high titre adenovirus stock (1×10^9 plaque forming units (pfu)/ml) was used for subsequent experiments.

**ANIMALS AND TREATMENT**

Eight week old female BALB/c mice, weighing 20–22 g, were purchased from Japan SLC Inc (Hamamatsu, Japan), supplied with food and water ad libitum, and exposed to a 12 hour light-dark cycle at a constant room temperature of 24 (2)°C. D-Galactosamine (GalN) is a α-amino sugar selectively metabolised by hepatocytes which induces depletion of the uridine triphosphate pool and thereby inhibition of macromolecule synthesis, such as RNA, proteins, and glycogen in the liver. When together with a low dose of lipopolysaccharide (LPS), GalN sensitises animals to the development of fulminant hepatitis. In contrast, intraperitoneal administration of thioacetamide (TAA) to mice is known to cause liver cirrhosis, characterised by hepato-cellular necrosis, increased connective tissue, and formation of regenerative nodules.

For the fulminant hepatitis model, mice were given intraperitoneal injections of TAA (Nacalai Tesque) (200 mg/kg body weight) suspended in phosphate buffered saline twice weekly for 32 weeks, beginning at 10 weeks of age. They received an intravenous injection of adenoviruses (200 µl/mouse) from the tail vein seven days after termination of TAA treatment. Ten week old mice with normal livers were used as controls. Animal experiments were performed with approved protocols and in accordance with recommendations for the proper care and use of laboratory animals.

**HISTOLOGICAL ANALYSIS**

To histologically examine the livers of animals that received GalN and LPS, or TAA, right lateral hepatic lobes were removed from animals, fixed in 10% buffered formaldehyde, and embedded in paraffin. Livers were sliced, stained with haematoxylin-eosin or Azan, and examined under light microscopy.

**IN VIVO TRANSDUCTION, X-gal STAINING, AND β-GALACTOSIDASE ACTIVITY**

Mice with normal, cirrhotic, and fulminant hepatitis livers were anaesthetised with ether, and 200 µl of adenovirus solution (1×10^9 pfu/ml) were injected into the tail vein. Animals were sacrificed four days after adenoviral injection. Each group consisted of eight animals. For histochemical staining, approximately half of the volume of the right lateral hepatic lobe from each animal was fixed with 10% buffered formaldehyde, 0.2% glutaraldehyde, and 0.02% Nonidet P-40 in 0.1 M sodium phosphate buffer (pH 7.4) for 60 minutes at room temperature. Livers were then sliced into 30 µm thick sections with a microslicer (DTK-3000; Dosaka EM, Kyoto, Japan). The slices were rinsed three times in phosphate buffered saline with 1 mM MgCl₂, and incubated overnight at 37°C in an X-gal (5-bromo-4-chloro-3-indolyl-β-galactosidase; Gibco, Grand Island, New York, USA) reaction mixture to detect lacZ gene expression, as described previously.

To quantitatively measure β-galactosidase activity induced by lacZ gene expression, a chemiluminescent reporter gene assay system using Galacton-Star (Tropix, Bedford, Massachusetts, USA) was used. Briefly, approximately half of the volume of the left median hepatic lobe from each animal was homogenised in a lysis buffer consisting of 100 mM potassium phosphate (pH 7.8) and 0.2% Triton X-100. Liver homogenates were centrifuged at 10 000 rpm for 10 minutes at 4°C. Supernatants were collected, and 1 µl of each supernatant sample was added to the reaction buffer containing the Galacton-Star chemiluminescent substrate. After incubation for 60 minutes at 37°C, β-galactosidase activity of the supernatant samples was measured using a luminometer (TR717 Microplate luminometer; Tropix). Protein concentrations of the supernatants were measured using the Bio-Rad (Hercules, California, USA) protein assay kit with bovine serum albumin as standard. Values were standardised based on the standard curve.
of *E coli* β-galactosidase (G-5635; Sigma) and expressed as pg of β-galactosidase/µg protein. Each estimation of β-galactosidase activity was performed in duplicate.

**EVALUATION OF ADVERSE EFFECT BY ADENOVIRAL ADMINISTRATION**

For evaluating the adverse effects of adenoviral administration, mice were subjected to thoracotomy, followed by collection of blood from the left ventricle of the heart, and serum biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH), albumin, total bilirubin, alkaline phosphatase, choline esterase, creatinine, and blood urea nitrogen (BUN) were measured in mice treated with and without intravenous administration of adenoviruses (2×10⁸ pfu/200 µl). Each group consisted of eight animals. For histological analysis of cytopathic effects caused by adenoviral administration, the left lateral hepatic lobe of each animal was removed, fixed in 10% buffered formalin, embedded in paraffin, and stained with haematoxylin-eosin.

**ADENOVIRUS SPECIFIC T CELL PROLIFERATION**

Activation of adenovirus specific splenic T cells was evaluated in a proliferation assay, as described previously. Briefly, spleen cells were collected from each animal and plated in duplicate in the wells of 96 well, flat bottomed plates (5×10⁵ cells/well). Cells were incubated with medium alone (background) or stimulated with heat inactivated (50°C for 20 minutes) recombinant adenoviruses at a multiplicity of infection of 100 pfu per cell in a total volume of 250 µl per well. Cells were incubated for five days at 37°C/5% CO₂, and pulsed with 1 µCi per well [³H] thymidine (Amersham, Aylesbury, UK) for the last 18 hours of incubation. Cells were harvested onto glass fibre filters with a 96 well plate cell harvester, and cell associated radioactivity was measured by liquid scintillation counting.

**NEUTRALISING ANTIBODY ASSAY**

Sera were measured for neutralising antibodies against adenovirus serotype 5 as previously described. Briefly, murine serum samples were incubated for 30 minutes at 56°C to inactivate complements and diluted in Dulbecco’s modified Eagle’s medium (DMEM) in twofold steps starting from 1:10 dilution. Each serum dilution (100 µl) was mixed with Adex1CAlacZ adenoviruses (2×10⁸ pfu in 10 µl), incubated for 60 minutes at 37°C, and applied to 80% confluent NIH3T3 cells in 96 well plates (2×10⁴ cells per well). After a 60 minute incubation period at 37°C, 100 µl of DMEM containing 20% heat inactivated fetal calf serum were added to each well. On the following day, cells were fixed and stained overnight with the X-gal solution. All cells were stained blue in the absence of serum samples. The titre of neutralising antibody for each sample was determined to be the reciprocal dilution that inhibited X-gal staining by 50%.

**STATISTICS**

Results are expressed as mean (SD). Standard descriptive statistics and Welch’s *t* test were used. *p*<0.05 was considered to indicate a significant difference between groups.

**Results**

**HISTOLOGICAL ANALYSIS OF CHEMICALLY INDUCED LIVER INJURY**

When we treated mice with GalN (500 mg/kg body weight) followed by LPS (0.1 µg/mouse), approximately 40% of animals died within 24 hours. Histological analysis using haematoxylin-eosin staining of the livers of mice who survived after 24 hours following GalN and LPS treatment revealed acute severe hepatitis with massive haemorrhagic necrosis of hepatocytes, disarray of the lobules, and marked infiltration of inflammatory cells (fig 1A). Azan staining of the livers of mice treated with thioacetamide for 32 weeks revealed an increase and thickening of the fibrotic septa, traversing the lobular parenchyma, and formation of pseudolobuli (fig 1B). (Original magnification ×40.)
by an increase and thickening of the fibrotic septa, traversing the lobular parenchyma by portovenous or portoporto bridging, thus promoting the formation of pseudolobuli (fig 1B).

lacZ GENE EXPRESSION IN THE LIVER

We first confirmed that no X-gal staining positive cells were observed in normal livers or in severely damaged livers of animals that were not given intravenous infusion of adenoviruses. Based on our previous study,24 25 we determined that peak lacZ gene expression in the liver induced by intravenous administration of recombinant adenoviruses occurred 2–7 days after administration. Therefore, we examined lacZ gene expression in normal and severely damaged livers of animals infused intravenously with 2×10⁸ pfu of adenoviruses four days after infusion. Although it is difficult to accurately estimate the rate of cells expressing the lacZ gene in the liver, morphometric evaluation of liver sections using the public domain NIH Image program (written by Wayne Rasband at the National Institutes of Health, Bethesda, Maryland, USA) revealed that approximately 40% of cells in normal livers expressed the lacZ gene (fig 2A). X-gal staining positive cells were seen predominantly at periportal areas, the so-called Rappaport’s zone 1, while a few positive cells were seen at centrilobular areas, the so-called zone 3. X-gal staining of cirrhotic livers induced by TAA revealed that X-gal staining positive cells occupied much larger areas of the liver compared with the normal liver, and that approximately 80% of cells in cirrhotic livers expressed the lacZ gene (fig 2B). Although positive cells were densely seen in zone 1, they spread from zone 1 to zone 2 and a considerable number of positive cells were also seen at zone 3. Histochemical analysis of fulminant hepatitis livers induced by GalN and LPS revealed that approximately 40% of liver areas were stained blue with X-gal staining (fig 2C). In contrast with the result of normal livers, X-gal staining positive cells were seen diffusely throughout fulminant hepatitis livers.

To quantitatively estimate levels of adenovirus mediated transgene expression in normal and severely damaged livers, livers were homogenised and β-galactosidase activity of the homogenates was measured using the chemiluminescent reporter gene assay system. Recombinant adenoviruses carrying the lacZ gene (2×10⁸ pfu/200 µl) were infused into the tail vein of mice. Livers were removed from animals four days after adenoviral infusion and β-galactosidase activity was measured. As shown in fig 3, β-galactosidase activity of normal livers was 25.0 (12.7) pg of β-galactosidase/µg protein. Although lacZ gene expression in fulminant hepatitis livers was significantly lower than that in normal livers, marked levels of β-galactosidase activity were detected even in fulminant hepatitis livers, with values of 11.8 (3.6) pg of β-galactosidase/µg protein. Conversely, lacZ gene expression in cirrhotic livers was significantly higher than that in normal livers, with β-galactosidase activity...
Table 1  Serum biochemical data in normal, cirrhotic, and fulminant hepatitis livers, before and after infusion of adenovirus

<table>
<thead>
<tr>
<th>Adenovirus infusion</th>
<th>Normal</th>
<th>Cirrhotic</th>
<th>Fulminant</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (u/litre)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>68.8 (10.9)</td>
<td>124.0 (33.40)</td>
<td>3311.7 (1313.7)</td>
</tr>
<tr>
<td>After</td>
<td>156.1 (38.7)*</td>
<td>260.1 (91.2)*</td>
<td>199.3 (72.3)*</td>
</tr>
<tr>
<td>None</td>
<td>ND</td>
<td>ND</td>
<td>177.9 (67.0)*</td>
</tr>
<tr>
<td>ALT (u/litre)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>24.3 (4.2)</td>
<td>51.0 (16.1)</td>
<td>4469.0 (1737.6)</td>
</tr>
<tr>
<td>After</td>
<td>30.7 (10.0)</td>
<td>84.0 (25.8)*</td>
<td>47.3 (38.8)*</td>
</tr>
<tr>
<td>None</td>
<td>ND</td>
<td>ND</td>
<td>87.0 (40.1)*</td>
</tr>
<tr>
<td>LDH (u/litre)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Before</td>
<td>724.8 (252.5)</td>
<td>712.3 (281.3)</td>
<td>90947 (2857.9)</td>
</tr>
<tr>
<td>After</td>
<td>2045.0 (331.9)*</td>
<td>1624.1 (528.7)*</td>
<td>1660.3 (836.7)*</td>
</tr>
<tr>
<td>None</td>
<td>ND</td>
<td>ND</td>
<td>1441.3 (916.8)*</td>
</tr>
</tbody>
</table>

*Data are mean (SD) of eight animals.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase, all expressed as units per litre at 37°C.
*Significantly different (p<0.05) from before administration of adenovirus, using Welch’s t test.
ND, not done.

activity being 66.0 (15.0) pg of β-galactosidase/μg protein.

CYTOPATHIC EFFECTS OF ADENOVIRAL ADMINISTRATION INTO NORMAL AND DAMAGED LIVERS

Although it has already been shown that intraportal or intravenous administration of adenoviruses provokes inflammation of the liver,2 22 25 the safety of adenoviral administration into animals with damaged livers remains to be examined. We infused 2×10^8 pfu of adenoviruses intravenously into mice with normal livers and also those with severely damaged livers. There were no treatment related deaths. We examined liver related serum biochemical parameters, such as ALT, AST, and LDH, before and four days after adenoviral administration. As shown in table 1, although serum levels of AST, ALT, and LDH increased after adenoviral administration in mice with normal livers and also in those with cirrhotic livers, the increase was not marked. Serum levels of AST, ALT, and LDH increased only 2.3-, 1.3- and 2.8-fold, respectively, in mice with normal livers, and only 2.1-, 1.6-, and 2.3-fold, respectively, in mice with cirrhotic livers. Conversely, serum levels of AST, ALT, and LDH decreased markedly in mice with fulminant hepatitis livers five days after treatment with GalN and LPS, regardless of adenoviral infusion, because of the lack of acute severe inflammation. Serum levels of AST, ALT, and LDH were not significantly different between mice with fulminant hepatitis livers treated with and without intravenous infusion of adenoviruses. Other liver related serum biochemical parameters, such as total bilirubin, albumin, alkaline phosphatase and choline esterase, as well as non-liver related parameters, such as creatinine and BUN, were not significantly different in mice with normal or cirrhotic livers before and after adenoviral infusion (data not shown). These parameters were not significantly different in mice with fulminant hepatitis livers treated with and without adenoviral infusion (data not shown).

We then examined if intravenous infusion of 2×10^8 pfu of adenoviruses into mice caused cytopathic effects in the liver. Histological analysis of normal livers revealed mild hepatitis-like pathological changes, such as hyperplastic changes in hepatocytes and infiltration of inflammatory cells. However, additional cytopathic effects caused by adenoviral infusion were not evident in cirrhotic livers due to the pre-existing inflammation (data not shown). Furthermore, consistent with the results of liver related biochemical parameters, severe inflammatory changes in fulminant hepatitis livers were absent regardless of the adenoviral infusion (data not shown). Although weak lacZ expression was detected by X-gal staining in the kidney, cytopathic effects were not observed histologically in the kidney of mice with normal or severely damaged livers (data not shown).

CELLULAR IMMUNE RESPONSE TO ADENOVIRUS

To examine cellular immune responses to adenovirus in mice with normal and severely damaged livers, activation of adenovirus specific splenic T cell proliferation was examined. Splenic cells collected from mice in the above experiments were incubated with heat inactivated adenoviruses which provides conditions that favour stimulation of CD4+ T cells as inactivated viral particles are processed by antigen presenting cells through the exogenous pathway of presentation, resulting in expression of viral peptides in association with MHC class II.21 As shown in fig 4, splenic cells collected from naive mice that had normal livers and did not receive intravenous infusion of adenoviruses did not proliferate significantly with stimulation with heat inactivated adenoviruses. Also, there were no significant differences in proliferation between adenovirus stimulated and unstimulated splenic cells collected from adeno virus injected mice with normal, cirrhotic, or fulminant hepatitis livers. Proliferation of splenic cells stimulated with
HUMORAL IMMUNE RESPONSE TO ADENOVIRUS

To examine humoral immune responses to adenovirus in mice with normal and severely damaged livers, serum samples were collected from mice in the above experiments and development of neutralising antibodies against adenovirus was examined. As shown in Fig. 5, mean titre of neutralising antibodies in animals with normal, cirrhotic, and fulminant hepatitis livers were ×700, ×540, and ×360, respectively, on day 4 after adenoviral infusion. Although the titre was lower in animals with damaged livers than in those with normal livers, the differences were not statistically significant.

Discussion

The feasibility of gene therapy for hepatocellular carcinoma (HCC) has been intensively investigated and HCC specific transgene expression was shown to be achievable by adenoviral vectors carrying an exogenous gene under the transcriptional control of the α-fetoprotein gene promoter. However, it should be emphasised that only a minority of HCCs arises de novo in non-cirrhotic livers and in the majority of cases HCC is found in conjunction with liver cirrhosis. Therefore, the efficiency and safety of adenovirus mediated gene transfer into cirrhotic livers but not into normal livers need to be estimated before gene therapy with adenoviruses is used clinically for the treatment of HCC. We have demonstrated that adenovirus mediated gene transfer can be performed efficiently and safely, even in cirrhotic livers. Furthermore, transduction efficiency of the reporter lacZ gene was shown to be higher in cirrhotic than in normal livers. Transgene expression was observed almost throughout the cirrhotic liver, while it was restricted mainly to zone 1 in the normal liver. Although the reason for the difference in transgene expression pattern remains unknown, a plausible explanation is that these phenomena occur as a result of differences in portal flow velocity. It is well known that the liver is supplied with blood mainly from the portal vein but not from the hepatic artery. Therefore, it is thought that the majority of adenoviruses infused intravenously reach the liver by way of the portal vein. It was shown that portal flow velocity was significantly decreased in patients with liver cirrhosis, and also that forward/backward flow of the portal blood was observed in cirrhotic patients due to a thrombus blood clot of the portal vein. Castelli and colleagues have shown that increasing the exposure time to adenoviruses provided a greater transduction efficiency in vitro. Taken together, these findings suggest that slow portal flow velocity carries adenoviruses more slowly from zone 1 to zone 3 through hepatic sinuses in cirrhotic livers than in normal livers and increases the contact time of adenoviruses to hepatocytes, resulting in a higher transduction efficiency and a larger transduction area of foreign genes in cirrhotic livers than in normal livers. Another explanation for the greater adenovirus mediated transduction of the foreign gene in cirrhotic livers is structural differences in the liver. The normally radial liver cell alignment is destroyed and fibrotic septa transversing the lobular parenchyma are present in cirrhotic livers. These structural changes may provide more space for adenoviruses to migrate into the liver.

In contrast with our results, Nakamura and colleagues have recently shown that adenovirus mediated transfer of the lacZ gene was markedly reduced in cirrhotic livers compared with normal livers. Although the investigators hypothesised that intralobular haemodynamics were reduced by formation of shunts between portal and central veins, resulting in markedly less transduction efficiency of the gene in cirrhotic livers, the existence of portovenous shunts in the rat cirrhosis model was not examined. They infused 1×10⁷ pfu of adenoviruses into the rat tail vein while we infused 2×10⁷ pfu of adenoviruses into the mouse tail vein. Therefore, the discrepancy in results does not appear to be due to the amount of adenovirus injected intravenously. Although the reasons for the discrepancy remain unknown, the difference may be attributed to the animal models used. They created a liver cirrhosis model by injecting CCI₄ intraperitoneally into rats while our model involved intraperitoneal injection of TAA into mice. Although Coxssackie/adenovirus receptors were shown to be highly expressed in the normal murine liver, little is known of expression of the receptors in murine and rat cirrhotic livers. Therefore, it will be important to perform further studies before drawing conclusions about the efficacy of adenovirus mediated gene transfer into the cirrhotic liver.

Fulminant hepatitis has a poor prognosis. Although liver transplantation has been shown to have an impact on survival, it is feasible in only a minority of patients because of the limited number of equipped hospitals, particularly...
Adenoviral administration into damaged livers

569

against adenovirus was not significantly different among animals with normal and severely damaged livers. This may result in varied migration of adenoviruses in fulminant hepatitis livers.

Adenoviruses are known to induce acute liver injury and elicit humoral and cellular immune responses. We also demonstrated previously that intraportal administration of adenoviruses resulted not only in development of neutralising antibodies against adenovirus but also in induction of adenovirus-specific T cells in rats. In the present study, we showed that efficient gene transduction into fulminant hepatitis livers was achieved by intravenous administration of adenoviruses without any significantly additional liver damage. Although the transduction efficiency of the lacZ gene into fulminant hepatitis livers by an adenoviral vector was lower than that in normal livers, considerable levels of transgene expression were observed. The reduced transduction efficiency in fulminant hepatitis livers appears reasonable because the number of parenchymal cells in fulminant hepatitis livers is much smaller than that in normal livers due to massive necrosis of the liver, resulting in a much smaller chance for adenoviruses to encounter hepatocytes. Interestingly, lacZ gene transduced cells were seen diffusely in fulminant hepatitis livers while transduced cells were seen predominantly in zone 1 of normal livers. The difference in the spread of X-gal staining positive cells may be due to structural differences. The normal hepatic structure is profoundly destroyed in fulminant hepatitis livers. This may result in varied migration of adenoviruses in fulminant hepatitis livers.

In summary, we have demonstrated that intravenous administration of adenoviruses into animals with cirrhotic or fulminant hepatitis livers resulted in efficient transduction and expression of the foreign gene in the liver without causing significant additional liver damage. Our results suggest that gene therapy using adenoviruses may be a feasible and promising therapeutic approach for the treatment of various diseases, even in patients with severe liver diseases.

This work was supported in part by a Grant-in-Aid for Scientific Research (B-10470140) from the Japanese Ministry of Education, Science, Sports, and Culture.


www.gutjnl.com


21 Kaplan JM, Smith AE. Transient immunosuppression with dexamethasone improves longevity of transgene expression and ability to re-administer adenoviral vector to the mouse liver. *Hum Gene Ther* 1997;8:1095–104.


www.gutjnl.com